

# PROACTIVELY IMPROVE DATA QUALITY AND REDUCE TRIAL RISK

### THE RISKS OF DATA QUALITY ISSUES

**24%**

applications that require one or more resubmissions before approval<sup>1</sup>

**52%**


resubmissions that had inconsistent study results<sup>1</sup>

**435 days**

median approval delay after a first unsuccessful submission<sup>1</sup>

### THE POWER OF MULTI-DIMENSIONAL OVERSIGHT TO IMPROVE YOUR STUDY DATA QUALITY AND ENSURE PATIENT SAFETY

With Medidata Detect, anomalies, outliers and trends across multiple variables are automatically detected, including unknown errors and risks outside of defined Key Risk Indicators (KRIs).



### THE IMMEDIATE IMPACT OF MEDIDATA DETECT

**20%-40%**

reduction in number of edit checks

**83%**

reduction in case review time by medical monitors

**50%-55%**

of data reviews automated

**5 days**

vs. ~4 weeks from LPLV to Database Lock for critical studies



On average **1 out of 6 trials are delayed by 3 months** because of quality issues. Medidata Detect is designed to minimize this risk.

Through statistical algorithms and tests, Medidata Detect uncovers data errors, trends, and anomalies and helps you **perform root-cause investigations and proactively take corrective actions.**

#### Oversight

Automate flagging of data anomalies  
Reduce risk of undetected anomalies  
Compute KRIs and provide early indication of clinically significant trends

#### Efficiency

50%-55% of data reviews automated  
20%-40% reduction in number of edit checks

#### Data Quality

Identify indications of potential misconduct  
Reduce risks of submission delays by submitting cleaner data

#### Simplification

Reduction from 30 days to 5 days for database lock in critical studies  
One central system for multiple review outputs (patient profiles, outlier detection, listings, KRIs, etc.)

1. Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier ML, Sherman RE, "Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012." JAMA. 2014;311(4):378-384. doi:10.1001/jama.2013.282542

### WHY MEDIDATA IN NUMBERS

**6.5M**

Trial Subjects

**780K+**

Sites

**14,000+**

Total Complete Trials

**70+**

Study Therapeutic Areas